Bio-rad Laboratories -cl B (BIO-B) 13F Holders & Ownership Data (5 Funds, Q2 2026)

BIO-B ranks #11881 out of 37503 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

5 institutions disclose a position in BIO-B, but none treat it as a major bet — even Flow Traders U.s. LLC, its most concentrated holder, allocates just 0.0% of its own portfolio to it.

UBS Group AG has added to its BIO-B position for two straight quarters, increasing it by $1.5K to reach $3.9K today.

BIO-B posted net income of $222.4M over the trailing twelve months, and currently trades at a P/E of 44.8.

• Profitable — net income of $222.4M over the trailing twelve months
• Revenue grew 1.4% year over year
• Net income declined year over year, from $319.2M to $222.4M
• Generated $532.2M in positive operating cash flow
• Current ratio of 5.62x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.42x equity — within a conventional range